OraSure Technologies, Inc.

347 articles with OraSure Technologies, Inc.

• OraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing

  6/14/2021

  OraSure Technologies, Inc. announced that it is collaborating with the Will Rodgers Liver Health Foundation to increase awareness around the role Hepatitis C plays in chronic liver disease and promoting testing services for HCV within the United States.

• OraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescription (OTC), Professional and Prescription Use

  6/7/2021

  OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 rapid antigen tests, which the Company is branding as InteliSwab™. These tests detect active COVID-19 infection. The FDA has authorized the InteliSwab ™ COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. FDA has also authorized the InteliSwa

• OraSure Technologies to Present at the Jefferies Virtual Healthcare Conference - May 28, 2021

  5/28/2021

  OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

• OraSure Technologies to Present at the UBS Global Healthcare Virtual Conference

  5/18/2021

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on May 26, 2021, at 2:00 PM EDT.

• OraSure Technologies Appoints Scott Gleason As Senior Vice President Investor Relations and Corporate Communications

  5/17/2021

  OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that Scott Gleason has been appointed Senior Vice President Investor Relations and Corporate Communications.

• OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 18, 2021

  5/12/2021

  OraSure Technologies, Inc., announced that its 2021 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern on Tuesday, May 18, 2021.

• OraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update

  5/5/2021

  First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 Million in Sales of Sample Collection Devices for COVID-19 Molecular Testing

• OraSure Technologies to Hold 2021 First Quarter Earnings Conference Call Wednesday, May 5, 2021, 5:00 p.m. ET

  4/30/2021

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, May 5, 2021. 

• OraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test and Professional Test to FDA for Emergency Use AuthorizationTests designed to detect active COVID-19 infection with a simple, easy-to-use workflow

  3/30/2021

  OraSure Technologies, Inc. announced that it has submitted an application to the U.S. Food and Drug Administration for Emergency Use Authorization of its COVID-19 rapid antigen test for both Prescription Home Use, and Professional Use in point of care settings.

• OraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update

  3/1/2021

  Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing COVID-19 Rapid Antigen Test clinical trials complete; OraSure plans to submit both a Prescription Self-Test and a Professional Test for EUA in Q1 Management to Host Conference Call and Webcast Today at 5:00 p.m. ET

• OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference

  2/24/2021

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raymond James 42nd Annual Institutional Investors Conference.

• 2020 Fourth Quarter Earnings Conference Call Monday, March 1, 2021, 5:00 p.m. ET

  2/18/2021

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2020 fourth quarter financial results and certain business developments for 5:00 pm ET on Monday, March 1, 2021.

• OraSure Subsidiary DNA Genotek’s OMNIgene®·ORAL Included in EUA Granted to Ambry Genetics for Use in COVID-19 RT-PCR Saliva TestThis is the Eighth EUA to Include a Self-Collection Device from DNA Genotek

  1/29/2021

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its OMNIgene®·ORAL saliva collection kit, a product of subsidiary DNA Genotek, was included in the Emergency Use Authorization granted to Ambry Genetics for use in its Ambry COVID-19 RT-PCR saliva test.

• OraSure Subsidiary DNA Genotek’s OMNIgene®·ORAL Saliva Collection Device Receives Health Canada Authorization for use in COVID-19 Testing

  1/28/2021

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its OMNIgene®·ORAL saliva collection device, a product of Ottawa-based subsidiary DNA Genotek, has received authorization from Health Canada for use as a component in molecular diagnostic tests for the detection of SARS-CoV-2.

• OraSure’s OMNIgene®·ORAL Saliva Collection Kit Selected by Chronomics for Use in UK Government “Test to Release for International Travel” COVID-19 Testing Program

  1/26/2021

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that Chronomics Limited has selected the OMNIgene®·ORAL saliva collection device as a component of its SARS CoV-2 PCR test.

• Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board

  1/25/2021

  Diversigen, Inc., a subsidiary of OraSure Technologies Inc., announced that Eric Pamer, M.D., Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board.

• OraSure’s Oragene®•Dx Saliva Collection Kit Included in Industry’s First FDA Authorization for a Whole Exome Sequencing Platform

  1/21/2021

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its Oragene®•Dx saliva collection device was included as a component in the De Novo authorization granted by the U.S. Food & Drug Administration to Helix for their Helix® Laboratory Platform1, a whole exome sequencing platform.

• OraSure Technologies Announces 2021 Annual Meeting Date

  1/8/2021

  OraSure Technologies, Inc. announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT on Tuesday, May 18, 2021.

• OraSure Technologies to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 39th Annual J.P. Morgan Healthcare Conference.

• OraSure’s OMNIgene®·ORAL Device Included in EUA Amendment Granted to 3B BlackBio Biotech India for SARS-CoV-2 Test

  12/23/2020

  OraSure Technologies, Inc. announced that its OMNIgene®·ORAL collection device was included in the U.S. Food and Drug Administration Emergency Use Authorization amendment granted to 3B BlackBio Biotech, one of the leading suppliers and developers for RT-PCR diagnostic assays in India.